Loading stock data…
Eupraxia Pharmaceuticals Inc. (EPRX)
$6.59-0.01 (-0.15%)
After Hours$6.59+0.00 (+0.00%)· Last close Jun 29
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eupraxia Pharmaceuticals Inc. in the Healthcare sector is trading at $6.59 with a market capitalization of $414M. Wall Street consensus targets $16.28 (9 analysts), implying a +147.0% move over the next 12 months. The stock is currently 29% below its 52-week high of $9.32, remaining 4.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +147.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.96M↑ | -$16.16M↓ | -$6.88M↑ | -$8.26M↓ | -$7.12M |
| Net Income | -$12.65M↑ | -$16.71M↓ | -$6.36M↑ | -$8.74M↓ | -$6.76M |
Peer Comparison
JNJUNHPFE
Fundamentals
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$413.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.27%
Volume
Today's trading volume
355,772
Recent News
Eupraxia Pharmaceuticals Q1 Loss Narrows
Eupraxia Pharmaceuticals' (EPRX.TO) first-quarter loss narrowed, the company said after trade on Tue
Eupraxia Reports Latest 36-Week Results From Resolve Trial
Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported the latest 36-week results for the highest dose
New Strong Sell Stocks for April 2nd
ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.
Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis Trial
Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported "positive data" from patients in the two highest
Eupraxia Pharmaceuticals Q4 Loss Widens
Eupraxia Pharmaceuticals (EPRX.TO) overnight Thursday reported a wider fourth-quarter net loss. T